



18<sup>th</sup> May 2017

Sydney, Australia

## ASX: NOX

### Noxopharm Limited

ABN 50 608 966 123

#### Registered Office:

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

#### Operations Office:

Suite 3 Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

#### Board of Directors

##### Mr Peter Marks

Chairman  
Non-Executive  
Director

##### Dr Graham Kelly

Chief Executive Officer  
Managing Director

##### Dr Ian Dixon

Non-Executive  
Director

## NOXOPHARM MID-YEAR INVESTOR BRIEFINGS

This is a general reminder that the Company is holding a series of mid-year briefings as follows:

- **Melbourne : Tuesday May 30<sup>th</sup> 11am - 12.30pm**  
Radisson on Flagstaff Gardens Hotel, 380 William St, Melbourne
- **Sydney: Friday June 2<sup>nd</sup> 1-2.30pm**  
Sydney Sofitel Wentworth, 61 - 101 Phillip St, Sydney
- **Gold Coast: Tuesday June 6<sup>th</sup>, 1.30-3.00pm**  
Surfers Paradise Marriott Resort Hotel, 158 Ferny Ave,  
Surfers Paradise

Noxopharm CEO , Dr Graham Kelly, and Director of Clinical Development and Medical Affairs, Mr Ian Minns, will present updates on the Company's NOX66 clinical programme and oncology and non-oncology R&D pipelines.

Enquiries: Prue Kelly 0459 022 445 or [info@noxopharm.com](mailto:info@noxopharm.com)

#### About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to radiotherapy and chemotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates

including idronoxil-C under development. The Company also has an expanding pipeline of non-oncology drugs.

---

### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.